Kuros Biosciences AG

LSE:0RHR Stock Report

Market Cap: CHF 759.0m

Kuros Biosciences Management

Management criteria checks 2/4

Kuros Biosciences' CEO is Chris Fair, appointed in Oct 2023, has a tenure of 1.17 years. total yearly compensation is CHF1.34M, comprised of 24.6% salary and 75.4% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth CHF2.69M. The average tenure of the management team and the board of directors is 1.2 years and 6.3 years respectively.

Key information

Chris Fair

Chief executive officer

CHF 1.3m

Total compensation

CEO salary percentage24.6%
CEO tenure1.2yrs
CEO ownership0.4%
Management average tenure1.2yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Fair's remuneration changed compared to Kuros Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CHF 9m

Mar 31 2024n/an/a

-CHF 11m

Dec 31 2023CHF 1mCHF 329k

-CHF 14m

Sep 30 2023n/an/a

-CHF 15m

Jun 30 2023n/an/a

-CHF 16m

Mar 31 2023n/an/a

-CHF 15m

Dec 31 2022CHF 36kn/a

-CHF 15m

Sep 30 2022n/an/a

-CHF 13m

Jun 30 2022n/an/a

-CHF 11m

Mar 31 2022n/an/a

-CHF 9m

Dec 31 2021CHF 36kn/a

-CHF 8m

Compensation vs Market: Chris's total compensation ($USD1.49M) is about average for companies of similar size in the UK market ($USD1.48M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Fair (54 yo)

1.2yrs

Tenure

CHF 1,337,700

Compensation

Mr. Christopher T. Fair, also known as Chris, serves as the Chief Executive Officer At Kuros Biosciences AG since October 2023 and serves as Director since April 17, 2024. He was the Chief Operating Office...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Fair
CEO & Director1.2yrsCHF 1.34m0.35%
CHF 2.7m
Daniel Geiger
Chief Financial Officer1.6yrsno datano data
Sjoerd Musters
COO & GM of BV1.2yrsno datano data
Joost de Bruijn
President of Innovation and Strategy & Executive Director1.2yrsCHF 873.70kno data
G. Ross
Senior Vice President of Marketing & Business Developmentless than a yearno datano data
Nikki Coleman
Vice President of Global Human Resourcesless than a yearno datano data
Philippe Saudan
Chief Development Officer8.3yrsno datano data
John Griffin
Chief Commercial Officer6.7yrsno datano data
Katherine Sage
Senior Vice President of Medical & Clinical Affairsless than a yearno datano data
Virginia Jamieson
Consultant6.6yrsno datano data

1.2yrs

Average Tenure

56yo

Average Age

Experienced Management: 0RHR's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Christopher Fair
CEO & Directorless than a yearCHF 1.34m0.35%
CHF 2.7m
Joost de Bruijn
President of Innovation and Strategy & Executive Director6.5yrsCHF 873.70kno data
Clemens van Blitterswijk
Chairman7.5yrsCHF 92.60k1.94%
CHF 14.7m
Oliver Walker
Independent Non-Executive Director6.5yrsCHF 73.80kno data
Cato Laurentin
Member of Advisory Boardno datano datano data
Ralph Müller
Member of Advisory Boardno datano datano data
Norbert Boos
Member of Advisory Boardno datano datano data
Thomas Steffen
Member of Advisory Boardno datano datano data
Andrew Sama
Member of Strategic Advisory Board6.3yrsno datano data
Richard Allen
Member of Strategic Advisory Board6.3yrsno datano data
Alpesh Patel
Member of Strategic Advisory Board6.3yrsno datano data
Kornelis Poelstra
Member of Strategic Advisory Board6.3yrsno datano data

6.3yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 0RHR's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 14:51
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kuros Biosciences AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Pfeifer-RossiBank am Bellevue
Olav ZilianMirabaud Securities Limited
Dylan van HaaftenNIBC Bank N.V.